Concord Drugs Ltd (CONCORD) is currently trading at 68.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Concord Drugs Limited is a Hyderabad-headquartered pharmaceutical contract manufacturer focused on finished formulations including injectables (small-volume parenterals and dry powder injections), tablets, capsules, ophthalmics and ready-to-fill pellets, operating cGMP formulation, fill and finish facilities and offering drug delivery innovations such as MUPS and sustained/modified release pellet systems. Financially the group delivered strong top-line growth for FY2026: consolidated revenue rose to Rs.7,877.13 lakhs from Rs.4,525.91 lakhs a year earlier, an approximately 74% increase driven by higher sales and expanded operations, while consolidated profit before tax improved to Rs.147.32 lakhs indicating improving operating scale and margin recovery versus the prior year. Corporate financing actions were material in FY2026: the company completed a preferential allotment of 31.75 lakh equity shares at Rs.36.30 and allotted 20.25 lakh warrants with 25% upfront payment, raising equity of Rs.317.50 lakhs and strengthening the balance sheet to fund expansion and working capital for manufacturing operations. Auditors flagged specific working-capital and control issues: long outstanding trade receivables of Rs.4.14 crores over two years remain unprovided for, closing stocks and several balances await third-party confirmations, and these exposures represent near-term credit and verification risks that could impact cash flows unless proactively addressed by Concord Drugs Limited.

Over the past 52 weeks, Concord Drugs Ltd has traded between a low of ₹63.00 and a high of ₹92.52. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Concord Drugs Ltd has a market capitalization of approximately 89.67. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Concord Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 43.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 89.67 Cr, Concord Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Concord Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Concord Drugs Ltd is 43.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.